Monitoring of bone turnover markers does not improve persistence with ibandronate treatment

Joint Bone Spine

Volumn 79, Issue 4, 2012, Pages 389-392

  Roux, Christian ^a   Giraudeau, Bruno ^b,c,d   Rouanet, Stéphanie ^e   Dubourg, Geneviève ^f   Perrodeau, Elodie ^b   Ravaud, Philippe ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d INSERM   (France)

^e Roche   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Bone turnover markers; Cluster randomisation; Osteoporosis; Persistence

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID;

ADULT; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; PATIENT CARE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES;

EID: 84863216048     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.05.001     Document Type: Article

References (23)

1. Tosteson A.N., Grove M.R., Hammond C.S., et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003, 115:209-216.
2. Caro J.J., Ishak K.J., Huybrechts K.F., et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003-1008.
3. Cramer J.A., Gold D.T., Silverman S.L., et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007, 18:1023-1031.
4. Cramer J.A., Amonker M.M., Hebborn A., et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453-1460.
5. Cotté F.E., Fardellone P., Mercier F., et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010, 21:145-155.
6. Gallagher A.M., Rietbrock S., Olson M., et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008, 23:1569-1575.
7. Penning-van Beest F.J., Erkens J.A., Olson M., et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008, 19:511-517.
8. Adami S., Isaia G., Luisetto G., et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006, 21:1565-1570.
9. Rabenda V., Mertens R., Fabri V., et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008, 19:811-818.
10. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013-1022.
11. Briot K., Ravaud P., Dargent-Molina P., et al. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 2009, 20:625-630.
12. Bell K.J.L., Hayen A., Macaskill P., et al. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ 2009, 338:b2266.
13. Delmas P.D., Vrijens B., Eastell R., et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of post menopausal osteoporosis. J Clin Endocrinol Metab 2007, 92:1296-1304.
14. Donner N., Klar N. Design and analysis of cluster randomisation trials 2000, Arnold, London, 178 p.
15. Giraudeau B, P Ravaud P. Preventing bias in cluster randomised trials. PLoS Med 2009;6(5):e 1000065.
16. Donner A., Donnal A. The statistical analysis of multiple binary measurements. J Chronic Dis 1988, 41:899-905.
17. Giraudeau B. Model mis-specification and overestimation of the intraclass correlation coefficient in cluster randomized trials. Stat Med 2006, 25:957-964.
18. Zou G., Donner, A Confidence interval estimation of the intraclass correlation coefficient for binary outcome data. Biometrics 2004, 60:807-811.
19. Clowes J.A., Peel N.F.A., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2008, 89:1117-1123.
20. Benner J.S., Glynn R.J., Mogun H., et al. Long term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-461.
21. Rossini M., Bianchi G., Di Munno O., et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006, 17:914-921.
22. Franke R.H., Kaul J.D. The Hawthorne experiments: first statistical interpretation. Am Sociol Rev 1978, 43:623-643.
23. Braunholts D.A., Edwards S.J., Lilford R.J. Are randomized clinical trials good for us? Evidence for a "trial effect" J Clin Epidemiol 2001, 54:217-224.